PubMed HealthSearch

PubMed · 909314

Vancomycin.

Abstract

Vancomycin, a useful bactericidal antibiotic for selective clinical infections, is the therapy of choice for serious staphylococcal infections when the penicillins and cephalosporins cannot be used. The antibacterial spectrum of vancomycin also covers other gram-positive cocci and bacteria and gram-negative cocci. Vancomycin is given intravenously in most cases, usually in a dose of 1 g every 12 hours in patients who have normal renal function. The indications for vancomycin therapy are as follows. 1. Serious staphylococcal infections in patients who are intolerant to the penicillins and cephalosporins or when the organism is resistant to the commonly used bactericidal agents. 2. Streptococcal endocarditis in patients intolerant to penicillin G; in enterococcal infections, it is used with an associated aminoglycoside. Vancomycin is not used alone in enterococcal endocarditis. In nonenterococcal (Streptococcus bovis) and viridans streptococcal endocarditis, vancomycin may be used alone if the minimum bactericidal concentration is less than or equal to 10 microgram/ml; otherwise, it is combined with an aminoglycoside. 3. Other serious infections caused by organisms resistant to the commonly used agents such as corynebacterial endocarditis. 4. Acute staphylococcal ileocolitis, for which vancomycin is given orally or orally and intravenously if indicated. Vancomycin is relatively nontoxic; the predominant toxic response is neurotoxicity, but this is rarely seen if the serum levels are 30 microgram/ml or less.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

J E Geraci. 1977. Vancomycin.. https://pubmed.ncbi.nlm.nih.gov/909314/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Acute rheumatic fever.

A funny thing has happened on our way to the elimination of rheumatic fever from the United States. It is quite clear that, at least in some areas, rheumatic fever has made a dramatic resurgence. Although all the factors accounting for this are not clearly understood, there are several obvious conclusions that must be drawn: 1. Rheumatic fever is no longer the province of the poor and overcrowded. 2. Clinical manifestations, as embodied in the Jones criteria, may have changed somewhat over the years. 3. New insights into the genetics and immunology of rheumatic fever may lead to a vaccine and/or effective therapy in the future. 4. Rheumatic fever will continue to occur unless and until we resume an aggressive approach to the treatment and prophylaxis of pharyngitis, probably utilizing benzathine penicillin as our primary drug.

Acute Disease

Epidemiology of invasive childhood pneumococcal infections in Israel. The Israeli Pediatric Bacteremia and Meningitis Group.

OBJECTIVE: To study the epidemiology of childhood pneumococcal invasive infections in Israel as a background for immunization programs. DESIGN: A 2-year (October 1988 through September 1990) prospective, nationwide surveillance of all invasive pediatric pneumococcal infections. SETTING: All 25 medical centers hospitalizing children in Israel, including all laboratories performing blood cultures from pediatric patients. PATIENTS: Infants and children aged 0 to 12 years visiting the pediatric emergency department or hospitalized in pediatric departments were included if Streptococcus pneumoniae was isolated from blood or cerebrospinal fluid. RESULTS: Four hundred sixty-nine invasive infections were diagnosed. Pneumonia, bacteremia without apparent focus, meningitis, and cellulitis were found in 39%, 37%, 17%, and 3%, respectively. The annual incidence was 42 per 100,000 for children younger than 5 years of age (104 per 100,000 for those < 12 months old). The two most common serotypes were 1 and 5, which are rare in Western Europe and North America. Eight groups comprised 82% of all invasive infections. Extrapolated to a population in which 100,000 live births occur yearly, the total annual hospitalizations for pneumococci infections was calculated to be 1928 days. The overall case-fatality rate was 2.2%, but it was 30% during the first month of life. CONCLUSIONS: Pneumococcal invasive infections are common in children in Israel and carry considerable morbidity.

Acute Disease